Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg2/20 cls
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)Cantor FitzgeraldIrina Rivkind KofflerPrice targetBuy61%$33.68
William BlairTim LugoPrice targetOutperform
Koffler raised her target to $37 from $30 after Eagle granted Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) exclusive rights to commercialize EP-3102 in the U.S. This month, Eagle submitted an NDA to FDA for the ready-to-dilute formulation of alkylating agent bendamustine to treat chronic

Read the full 621 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers